Global Market for Hormone Refractory Breast Cancer to be Driven by Demand for More Effective Therapeutics
A new market research study by Transparency Market Research offers an in-depth analysis of the global market for hormone refractory breast cancer. The research report, titled “Hormone Refractory Breast Cancer Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 – 2020,” covers the product segmentation, current trends, key geographical segments, growth drivers, restraints, and competitive scenario.
You can download a sample for free:
The research study also offers projected statistics and historical information of the global market to guide the existing and new players in formulating business strategies effectively. Several analytical tools have also been used in the research report to determine the growth prospects and opportunities for the major players operating in the global market.
Breast cancer is one of the most common types of cancer that is affecting women in both developed and developing regions at an alarming rate. The growing prevalence of hormone refractory breast cancer is the key factor fuelling the growth of the market. In addition, the growing demand for advanced therapeutics and a rising number of drugs in the pipeline are further projected to contribute substantially towards the growth of the market.
By geography, the global market for hormone refractory breast cancer has been divided into North America, Asia Pacific, Europe, and Rest of the World. In the last few years, North America and Europe have been dominant regional markets. As per the study, these two regions are projected to lead the market through the report’s forecast period. The rapid growth of North America and Europe can be attributed to the growing base of patients suffering from hormone refractory breast cancer and the increasing geriatric population.
In addition, the growing number of drug developers in Europe and North America are expected to contribute substantially towards the growth of the hormone refractory breast cancer market throughout the forecast period. On the other hand, the Asia Pacific market for hormone refractory breast cancer is projected to witness rapid growth in the next few years, owing to the expanding healthcare sector and increasing purchasing power of consumers.
The research study further offers a detailed vendor analysis of the global market for hormone refractory breast cancer and throws light on the competitive scenario for the same. Some of the leading players operating in the global market for hormone refractory breast cancer are AmpliMed Corporation, Boehringer Ingelheim GmbH, Bluefish Pharmaceuticals AB, F. Hoffmann-La Roche Ltd., Neopharm Ltd., Bioenvision Limited, NeoCorp GmbH, and AstraZeneca plc. Detailed profiles of these players have been included in the scope of the research report.